share_log

和誉-B(02256.HK):开展ABSK043与甲磺酸伏美替尼片联合用药治疗晚期非小细胞肺癌的临床研究

Heyu-B (02256.HK): Carrying out clinical research on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer

Gelonghui Finance ·  May 8 18:27

On May 9, Gelonghui | Heyu-B (02256.HK) announced that ABSK043, an oral small molecule PD-L1 inhibitor it is developing, will soon cooperate with vometinib mesylate tablets independently developed by Allis (688578.SH) (trade name: Avsha), “vometinib”) is carrying out clinical research on combination treatment for advanced non-small cell lung cancer.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment